Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports

Anthropic has acquired Coefficient Bio, a biotech AI startup, in a $400M deal to enhance its healthcare initiatives. Coefficient Bio, founded by former Genentech employees, specializes in AI-driven drug discovery. This acquisition aligns with Anthropic’s focus on leveraging AI for advancements in life sciences, following their recent tool launch, Claude for Life Sciences.

Key Points

• Anthropic purchased Coefficient Bio for $400M in stock.
• The deal was confirmed to closed per sources but amount details were withheld.
• Coefficient Bio specializes in AI for drug discovery and was founded 8 months ago.
• Founders Samuel Stanton and Nathan C. Frey previously worked in computational drug discovery.
• The team of about 10 will integrate into Anthropic’s health and life science division.

Relevance

• The acquisition reflects a growing trend in AI integration into healthcare and biotech.
• Anthropic is expanding its AI capabilities in line with increased investment in biotech startups.
• AI’s role in drug discovery is critical as the industry shifts towards more automated and efficient methods.

This acquisition signifies Anthropic’s commitment to revolutionizing healthcare through AI technology, mirroring broader trends in the industry towards enhanced efficiency in drug discovery.